Re-evaluation of HER2 status in 606 breast cancers—gene protein assay on tissue microarrays versus routine pathological assessment

Human epidermal growth factor receptor 2 (HER2) status in breast cancer is routinely determined through immunohistochemistry (IHC) and/or in situ hybridisation (ISH) performed on whole tissue sections (WS). The purpose was to evaluate whether a gene protein assay (GPA) combining IHC with ISH, perfor...

Descripción completa

Detalles Bibliográficos
Autores principales: Sandén, Emma, Khazaei, Somayeh, Tryggvadottir, Helga, Borgquist, Signe, Isaksson, Karolin, Jirström, Karin, Jernström, Helena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7371653/
https://www.ncbi.nlm.nih.gov/pubmed/32080761
http://dx.doi.org/10.1007/s00428-020-02768-x
_version_ 1783561150249566208
author Sandén, Emma
Khazaei, Somayeh
Tryggvadottir, Helga
Borgquist, Signe
Isaksson, Karolin
Jirström, Karin
Jernström, Helena
author_facet Sandén, Emma
Khazaei, Somayeh
Tryggvadottir, Helga
Borgquist, Signe
Isaksson, Karolin
Jirström, Karin
Jernström, Helena
author_sort Sandén, Emma
collection PubMed
description Human epidermal growth factor receptor 2 (HER2) status in breast cancer is routinely determined through immunohistochemistry (IHC) and/or in situ hybridisation (ISH) performed on whole tissue sections (WS). The purpose was to evaluate whether a gene protein assay (GPA) combining IHC with ISH, performed on breast cancer tissue microarray (TMA), is suitable for large-scale retrospective HER2 status evaluation. TMAs from 606 tumours from a Swedish population-based cohort (2005–2012) were stained with GPA. GPA IHC on TMA yielded weaker staining than IHC on WS during routine pathological assessment (86.0% agreement). However, final HER2 status agreement between GPA on TMA and WS based on both IHC and ISH was 97.7%. Only 14 tumours were discordant and one tumour with IHC score 1+ on both TMA and WS was HER2 amplified on TMA. In conclusion, GPA on TMA is suitable for large-scale retrospective evaluation of HER2 status.
format Online
Article
Text
id pubmed-7371653
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-73716532020-07-22 Re-evaluation of HER2 status in 606 breast cancers—gene protein assay on tissue microarrays versus routine pathological assessment Sandén, Emma Khazaei, Somayeh Tryggvadottir, Helga Borgquist, Signe Isaksson, Karolin Jirström, Karin Jernström, Helena Virchows Arch Brief Report Human epidermal growth factor receptor 2 (HER2) status in breast cancer is routinely determined through immunohistochemistry (IHC) and/or in situ hybridisation (ISH) performed on whole tissue sections (WS). The purpose was to evaluate whether a gene protein assay (GPA) combining IHC with ISH, performed on breast cancer tissue microarray (TMA), is suitable for large-scale retrospective HER2 status evaluation. TMAs from 606 tumours from a Swedish population-based cohort (2005–2012) were stained with GPA. GPA IHC on TMA yielded weaker staining than IHC on WS during routine pathological assessment (86.0% agreement). However, final HER2 status agreement between GPA on TMA and WS based on both IHC and ISH was 97.7%. Only 14 tumours were discordant and one tumour with IHC score 1+ on both TMA and WS was HER2 amplified on TMA. In conclusion, GPA on TMA is suitable for large-scale retrospective evaluation of HER2 status. Springer Berlin Heidelberg 2020-02-20 2020 /pmc/articles/PMC7371653/ /pubmed/32080761 http://dx.doi.org/10.1007/s00428-020-02768-x Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Brief Report
Sandén, Emma
Khazaei, Somayeh
Tryggvadottir, Helga
Borgquist, Signe
Isaksson, Karolin
Jirström, Karin
Jernström, Helena
Re-evaluation of HER2 status in 606 breast cancers—gene protein assay on tissue microarrays versus routine pathological assessment
title Re-evaluation of HER2 status in 606 breast cancers—gene protein assay on tissue microarrays versus routine pathological assessment
title_full Re-evaluation of HER2 status in 606 breast cancers—gene protein assay on tissue microarrays versus routine pathological assessment
title_fullStr Re-evaluation of HER2 status in 606 breast cancers—gene protein assay on tissue microarrays versus routine pathological assessment
title_full_unstemmed Re-evaluation of HER2 status in 606 breast cancers—gene protein assay on tissue microarrays versus routine pathological assessment
title_short Re-evaluation of HER2 status in 606 breast cancers—gene protein assay on tissue microarrays versus routine pathological assessment
title_sort re-evaluation of her2 status in 606 breast cancers—gene protein assay on tissue microarrays versus routine pathological assessment
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7371653/
https://www.ncbi.nlm.nih.gov/pubmed/32080761
http://dx.doi.org/10.1007/s00428-020-02768-x
work_keys_str_mv AT sandenemma reevaluationofher2statusin606breastcancersgeneproteinassayontissuemicroarraysversusroutinepathologicalassessment
AT khazaeisomayeh reevaluationofher2statusin606breastcancersgeneproteinassayontissuemicroarraysversusroutinepathologicalassessment
AT tryggvadottirhelga reevaluationofher2statusin606breastcancersgeneproteinassayontissuemicroarraysversusroutinepathologicalassessment
AT borgquistsigne reevaluationofher2statusin606breastcancersgeneproteinassayontissuemicroarraysversusroutinepathologicalassessment
AT isakssonkarolin reevaluationofher2statusin606breastcancersgeneproteinassayontissuemicroarraysversusroutinepathologicalassessment
AT jirstromkarin reevaluationofher2statusin606breastcancersgeneproteinassayontissuemicroarraysversusroutinepathologicalassessment
AT jernstromhelena reevaluationofher2statusin606breastcancersgeneproteinassayontissuemicroarraysversusroutinepathologicalassessment

Ejemplares similares